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Human and mouse essentiality screens
as a resource for disease gene discovery
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The identiﬁcation of causal variants in sequencing studies remains a considerable challenge
that can be partially addressed by new gene-speciﬁc knowledge. Here, we integrate measures
of how essential a gene is to supporting life, as inferred from viability and phenotyping
screens performed on knockout mice by the International Mouse Phenotyping Consortium
and essentiality screens carried out on human cell lines. We propose a cross-species gene
classiﬁcation across the Full Spectrum of Intolerance to Loss-of-function (FUSIL) and
demonstrate that genes in ﬁve mutually exclusive FUSIL categories have differing biological
properties. Most notably, Mendelian disease genes, particularly those associated with
developmental disorders, are highly overrepresented among genes non-essential for cell
survival but required for organism development. After screening developmental disorder
cases from three independent disease sequencing consortia, we identify potentially patho-
genic variants in genes not previously associated with rare diseases. We therefore propose
FUSIL as an efﬁcient approach for disease gene discovery.
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D iscovery of the genetic causes of monogenic disorders hasshifted from genetic analysis of large cohorts or familieswith the same phenotype to a genotype-driven approach
able to identify ultra-rare variants associated with a disorder in
one or few individuals. Published studies by the Centers for
Mendelian Genomics (CMG)1, Deciphering Developmental Dis-
orders (DDD)2,3 and the Undiagnosed Disease Network4 have
successfully used whole-exome or genome sequencing to ﬁnd the
causal variant in up to 40% of patients. However, the majority of
cases remain unsolved. One complimentary approach has been to
incorporate gene-level information metrics. These metrics can
help to identify candidate variants in genes not previously asso-
ciated with disease, which are subsequently conﬁrmed as causa-
tive in functional in vitro and in vivo studies. Measures of genetic
intolerance to functional variation have been used to prioritise
candidate disease genes where heterozygous, dominant effects are
suspected. These metrics are based on whole-exome and genome
sequencing data from broad populations of healthy individuals or
cohorts affected by non-severe and non-paediatric disease5–7.
Use of standardised gene–phenotype associations encoded by
the Human Phenotype Ontology (HPO)8 is another successful
strategy that has led to the identiﬁcation of disease genes by the
phenotypic similarity of patients9. Phenotype comparison
between model organisms and clinical descriptions has also
highlighted new candidate gene–disease associations10. These
successes led us to consider other gene features that could be used
to identify human disease genes.
Gene essentiality, or the requirement of a gene for an
organism’s survival, is known to correlate with intolerance to
variation11 and has been directly assessed in a number of
species using high-throughput cellular and animal models12–14.
Essentiality has been investigated at the cellular level using
human cancer cell line screens based on gene-trap, RNAi or
CRISPR-Cas9 approaches with the ﬁndings that ~10% of
protein-coding genes are essential for cell proliferation and
survival15–18. Project Achilles is extending this approach to
characterise 1000 cancer cell lines, importantly correcting for
copy number in their essentiality scoring19,20. In parallel, the
International Mouse Phenotyping Consortium (IMPC), a global
research infrastructure that generates and phenotypes knockout
(loss of function (LoF)) mouse lines for protein-coding
genes, determines viability of homozygotes to assess gene
essentiality10,21,22. The number of observed homozygous LoF
mice generated from an intercross between heterozygous par-
ents allows the categorisation of a gene as lethal (~25% of the
genes), subviable (~10%) or viable (~65%)18,21. These ﬁndings
are consistent with results curated from the scientiﬁc literature
indicating that approximately one-third of protein-coding
genes are essential for organism survival23.
Several levels or deﬁnitions of essentiality are to be expected
from different approaches13. Core essential genes are identiﬁed
across different model systems, while other essential genes are
dependent on context such as culture conditions, tissue or
organism developmental stage24–26. Quantitative deﬁnitions of
low and high gene essentiality have been proposed to account for
the degree of dependency on external factors, as well as the
likelihood of a compensatory mutation rescuing necessary func-
tion26 through mechanisms, such as paralogue buffering15,27.
Essential genes have also been classiﬁed by whether they are
known to be associated with human disease, with functional
mutations in non-disease-associated genes and with a mouse
orthologue that is LoF embryonic lethal suggested as likely to
prevent pregnancy, lead to miscarriage or to early death28. Other
research has reported that orthologues of embryonic lethal LoF
mouse genes show an increased association with diseases with
high mortality and neurodevelopmental disorders21,29,30.
Here we provide a new Full Spectrum of Intolerance to Loss-
of-function (FUSIL) categorisation that functionally bins human
genes by taking advantage of the comprehensive organismal
viability screen performed by the IMPC and the cellular viability
studies conducted by Project Achilles. We explore the FUSIL
categories that span genes from those necessary for cellular sur-
vival to genes for which LoF has no detected phenotypic impact
on complex organisms, and we demonstrate a strong correlation
of genes necessary for mammalian development with genes
associated with human disease, especially early-onset, multi-sys-
tem, autosomal-dominant (AD) disorders. Finally, we describe
candidate genes for involvement in AD, developmental disorders
where potentially pathogenic variants were identiﬁed in unsolved
cases from three large-scale exome and genome data sets: the
DDD Study3, the 100,000 Genomes Project (100KGP)31, and the
CMG programmes1.
Results
Functional binning of viability by cross-species comparison.
Human cell-essential genes have been analysed15–17 in conjunc-
tion with lethal genes identiﬁed in the mouse21 by characterising
a core set of essential genes at the intersection13, studying the
union of the two32 or considering them as two separate sets33. In
these studies, cellular essential genes showed a nearly complete
concordance with mouse lethal genes18,21. Here we have taken the
human orthologue genes for which the IMPC has viability
assessments and integrate the gene essentiality characterisation
based on the cell proliferation scores determined by the Project
Achilles Avana CRISPR-Cas9 screening performed on over 400
cell lines. This identiﬁed two sets of lethal genes: a set of cellular
lethal genes essential for both a cell and an organism to survive
(cellular lethal (CL)), and a set of developmental lethal genes (DL)
that are not essential at the cellular level but where LoF is lethal at
the organism level. The IMPC viability pipeline also deﬁnes genes
that result in a subviable (SV) or viable phenotype in LoF mice.
We further split the latter into those resulting in an abnormal
phenotype (VP, viable with signiﬁcant phenotype/s) or a normal
phenotype (VN, viable with no signiﬁcant phenotypes detected).
As a result, we obtained ﬁve mutually exclusive phenotype cate-
gories reﬂecting the FUSIL (Table 1; Supplementary Table 1). The
correspondence between viable and SV genes in the mouse and
their human orthologues being non-essential in human cell lines
was very strong (Table 1, Fig. 1a). An almost complete corre-
spondence was also found between genes essential in human cell
lines and mouse genes that are lethal in LoF strains. However,
while 35% of genes lethal in the mouse were essential in human
cell lines (CL bin), the remaining 65% have not been identiﬁed as
cell essential and were classiﬁed as essential for organism devel-
opment (DL bin). A near identical pattern was observed when
other cellular essentiality data sets were used from previously
published studies15–17, with most genes ending up in the same
category (96% overlap; Supplementary Fig. 1c, Supplementary
Table 2).
Biological process and pathway analysis. An enrichment ana-
lysis of Gene Ontology (GO) biological processes (BPs) showed
that the two lethal FUSIL categories (CL and DL) were involved
in different types of biological processes (Fig. 1b, Supplementary
Data 1). Whereas the set of CL genes was enriched for nuclear
processes (DNA repair, chromosome organisation, regulation of
nuclear division), the DL genes were enriched in morphogenesis
and development functions (embryo development, appendage
development, tissue morphogenesis, speciﬁcation of symmetry).
In contrast, genes in the SV and viable categories (VP, VN)
were not signiﬁcantly enriched in any biological process despite
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Table 1 FUSIL categories.
Mouse category Human cell line category Number of genes % Overlap FUSIL category
Lethal Essential 413 35.09% Cellular lethal (CL)
Lethal Non-essential 764 64.91% Developmental lethal (DL)
Subviable Essential 16 3.66% —
Subviable Non-essential 421 96.34% Subviable (SV)
Viable with phenotypic abnormalities Essential 18 0.95% —
Viable with phenotypic abnormalities Non-essential 1867 99.05% Viable with phenotype (VP)
Viable with normal phenotype Essential 2 0.62% —
Viable with normal phenotype Non-essential 318 99.38% Viable with no phenotype (VN)
Integration of data from human cell essentiality screens from the Avana data set and mouse phenotypes from IMPC screens for 4446 protein-coding genes that have data in both resources and a high-
quality orthologue. This deﬁned ﬁve mutually exclusive categories of intolerance to loss of function and the number of human protein-coding genes is shown for each. For 627 of the viable mouse lines,
the number of procedures with QCed data available was <50% and thus they were classiﬁed as Viable with insufﬁcient procedures (see “Methods”, Supplementary Table 1) and not incorporated into
these FUSIL categories. The Viable with phenotype (VP) category indicates that the phenotypes of the knockout (loss of function) mouse line differ signiﬁcantly from the wild-type mice in at least one of
the many parameters measured as part of the IMPC phenotyping pipeline (average of 163 parameters measured on any given mouse).
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Fig. 1 Cross-species FUSIL categories of intolerance to LoF. a Correspondence between primary viability outcomes in mice and human cell line screens.
The sankey diagram shows how human orthologues of mouse genes with IMPC primary viability assessment (lethal, subviable and viable) regroup into
essential and non-essential human cell categories; the width of the bands is proportional to the number of genes. b Gene Ontology Biological Process (GO
BP) enrichment results. Signiﬁcantly enriched GO terms at the biological process level were computed using the set of IMPC mouse-to-human orthologues
incorporated into the FUSIL categories as a reference (Table 1) and identiﬁed after correcting for multiple comparisons. Signiﬁcant results were only found
for the cellular and developmental lethal gene categories. Bubble size is proportional to the frequency of the term in the database and the colour indicates
signiﬁcance level as obtained in the enrichment analysis. The GO terms associated with embryo development are in bold. c Correspondence between
mouse embryonic lethality stage and essentiality in human cell lines. Embryonic lethal LoF strains are assessed for viability at selected stages during
embryonic development: early (gestation) lethal (prior to E9.5), mid (gestation) lethal (E9.5–E14.5/15.5), late (gestation) lethal (E14.5/E15.5 onwards).
E embryonic day.
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reasonable sample sizes, probably indicating diverse roles for
these genes. A pathway analysis showed consistent results, with
genes belonging to cell cycle and DNA-associated pathways sig-
niﬁcantly overrepresented among CL genes. Developmental
biology pathways, on the other hand, were only found enriched
among DL genes (Supplementary Fig 2, Supplementary Data 2).
GO BP analysis showed numerous enriched RNA-processing
terms mainly in the CL category. Related processes involving
RNA polymerase and transcription were nominally enriched in
the DL fraction, reﬂecting how transcriptional regulation is cen-
tral to organism development. Taken together, these analyses
provide additional evidence to make a distinction between the
two sets of lethal genes in terms of their biological function.
Cellular essential genes correlate with early lethal genes. For
those genes found to be lethal, the IMPC performed a secondary
viability assessment of null homozygous embryos to determine
the time of embryonic death. Four hundred lethal genes were
classiﬁed in one of the three windows of lethality: early gestation
(49.25%), mid-gestation (12.50%), and late gestation lethal genes
(38.25%), conﬁrming previous ﬁndings that nearly half of
lethal mouse genes with an embryonic screening correspond to
embryos which die prior to embryonic day 9.5 (E9.5)21. When
this information was combined with the human cell data set, we
observed a strong concordance between the stage of embryo
lethality and essentiality at the cellular level: 65% of early gesta-
tion lethal genes are essential in human cell lines, whereas only
10% of mid-gestation lethal genes and <5% of late gestation lethal
genes fall into this category (Fig. 1c, Supplementary Table 3).
FUSIL categories and associated gene features. In humans,
essential genes have been shown to be located in regions with
lower recombination rates34. We observe a trend of increasing
recombination rate from most to least essential, with CL genes
representing a clearly distinct category and signiﬁcant differences
between bins for most pairwise comparisons (Fig. 2a, Supple-
mentary Table 4). Consistent with higher expression values pre-
viously associated with essential genes15, we show a decreasing
trend in human gene expression levels from most to least essential
FUSIL bins, as measured by median GTEx expression across a
wide range of tissues and cell lines (Fig. 2b). Similar continuous
trends were observed for other gene features previously associated
with essential genes15,28,35, including protein–protein interaction
network properties (Fig. 2c) or the likelihood of the gene product
being part of a protein complex (Fig. 2d). CL genes also stand
out as a singular category regarding the number of paralogues
(Fig. 2e).
In contrast, features associated with mutational rate appear to
peak in the DL or SV bins: probability of mutation based on gene
context (Fig. 2f), transcript length (Fig. 2g), and strength of
negative selection measured by Gene-level Integrated Metric of
negative Selection (GIMS) scores (Fig. 2h). However, these
observed increases in the DL and SV genes relative to CL were
only statistically signiﬁcant for transcript length (Supplementary
Table 4). A similar effect is observed with several intolerance to
variation scores from the Genome Aggregation Database
(gnomAD). Higher (but not statistically signiﬁcant) probability
of LoF intolerance (pLI) values were observed in the DL and SV
genes relative to CL, with a lower frequency of pLI values close to
0 among the viable bins when compared to the CL, DL and SV
sets (Fig. 2i, Supplementary Fig. 3, Supplementary Table 5).
A reverse trend, given the nature of this metric, was detected for
the observed/expected (o/e) LoF scores (upper bound fraction)
(Fig. 2j).
Developmental lethal bin is enriched in human disease genes.
Previous studies have reported associations between disease and
essential genes using different criteria and data sets29,36. Our
ﬁrst report on developmental phenotypes showed a signiﬁcant
enrichment for disease genes in the IMPC essential genes21.
By segmenting this set of genes into three mutually exclusive
categories (CL, DL and SV; Fig. 3a), we found that while the CL
and SV fractions showed a moderate enrichment for disease genes
compared to all other categories (odds ratios (ORs) > 1) and the
two bins containing viable genes (VP and VN) were signiﬁcantly
depleted (ORs < 1), the highest overrepresentation of Mendelian
disease genes was found in the DL fraction (2.6-fold increased
odds). This ﬁnding was consistent with an early study deﬁning a
set of peripheral essential genes25 and a recent review comparing
cellular and mouse essential genes33.
Analysis of the mode of inheritance of the disease genes in each
bin showed the CL fraction had the lowest proportion of AD
disorders, while the DL and VN fractions showed higher
proportions (uncorrected P values of 0.0143 and 0.004,
respectively, Fisher’s exact test) (Fig. 3b). The latter, however,
was based on a relatively small number of disease genes (40) with
AD/autosomal-recessive (AR) annotations in this category
relative to 119 and 286 seen in the CL and DL fractions,
respectively. The proportion of known haploinsufﬁcient genes
among disease genes was greatest in the DL fraction with twice as
many as in the CL fraction (Fig. 3c).
We analysed the FUSIL categories for gnomAD’s o/e LoF
scores (upper bound fraction), which are used to evaluate a gene’s
tolerance to LoF variation. Our results showed that essential
genes are more intolerant to inactivation compared to viable
genes and that the DL and SV categories showed the peak
intolerance although the difference with respect to the set of CL
genes was not signiﬁcant (Fig. 2j, Supplementary Table 5). Again,
this is consistent with an overrepresentation of AD disorders
among DL genes. Similar results were found when we investigated
other intolerance scores (Supplementary Fig. 3, Supplementary
Table 5).
The proportion of disease genes associated with an early age of
onset (antenatal/prenatal and neonatal) was highest in the CL and
DL gene sets, with the percentage of later-onset associated
genes increasing as we move toward more viable categories
(Fig. 3d). The degree of pleiotropy, measured by the number of
physiological systems affected according to HPO annotations,
followed a similar pattern, with CL and DL genes showing the
highest number of affected systems (Fig. 3e).
In summary, our results suggest that disease genes in the DL
fraction correlated with earlier age of onset, multiple affected
systems and AD disorders (Supplementary Table 6). Given this, we
compared the genes in our FUSIL bins with the genes identiﬁed as
likely to be causative of developmental disorders in the DDD Study
as reported in the Development Disorder Genotype–Phenotype
Database (DDG2P) and found a strong enrichment for these genes
in the DL FUSIL bin (3.9-fold increase; Fig. 3f). The DDDG2P
resource has a larger representation of non-consanguineous patients
with de novo mutations compared to the OMIM and Orphanet
resources37, so we next compared enrichment of DL genes by mode
of inheritance across the three resources and found the strongest
enrichment for monoallelic disease genes in the DDDG2P resource
(Fig. 3g, h).
These ﬁndings were corroborated when we explored
diagnostic-grade genes that have a high level of evidence for
disease associations as curated by experts for Genomics England
(Supplementary Fig. 4). The DL category showed an even higher
enrichment in developmental disease-associated genes for a
subset of highly conﬁdent genes from DDG2P3 (4.4-fold increase;
Supplementary Fig. 4e) and as did a set of genes associated with
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foetal anomalies from the PAGE Consortium38 (4.9-fold increase;
Supplementary Fig. 4f).
These results are particularly relevant for the identiﬁcation of
new disease genes using these FUSIL bins: for Mendelian genes,
despite the enrichment in the DL fraction, the highest proportion
was still found in the much larger VP bin (Fig. 3a, g), but for
developmental disorders, as represented by DDG2P, the DL
fraction contained the majority of genes, reaching a percentage
close to 50% for monoallelic disease genes (Fig. 3g, h), and up to
57% when different curated subsets of genes involved in
developmental disorders and foetal anomalies were investigated
(Supplementary Fig. 4g, h). Thus, we attempted to identify strong,
novel candidate genes for undiagnosed cases of AD, development
disorders by extracting 163 genes from the DL bin genes (n=
764), which had the following properties: (i) not described as
associated with human disease by OMIM, Orphanet or DDG2P
and (ii) highly intolerant to a LoF mutation (pLI > 0.90 or o/e LoF
upper bound < 0.35 or haploinsufﬁciency (HI) score < 10). These
163 prioritised DL genes are more likely to belong to the same
protein family or biological pathway of known monoallelic
developmental disease genes and more frequently interact with
them when compared to genes across the FUSIL bins not
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associated with disease (Supplementary Fig. 5, Supplementary
Data 3). Only the set of non-disease CL genes showed similar
results regarding pathways and interactors.
Screening of unsolved developmental disorder cases. We next
focussed on unsolved diagnostic cases from three large rare
disease sequencing programmes to investigate potential disease
candidates within our set of 163 prioritised DL genes
(Supplementary Data 4).
First, DDD makes publicly available a set of functional de novo
variants and/or rare homozygous, hemizygous or compound
heterozygous LoF research variants of unknown signiﬁcance
found in genes that are not associated with human disease
according to OMIM and DDG2P. These variants were found in
4293 children with developmental disorders who participated in
the UK DDD study and remained undiagnosed. Given recent
ﬁndings from DDD that most developmental disorder cases could
be explained by de novo coding mutations37, we searched for
heterozygous, de novo variants in this data set that affected any of
the prioritised 163 DL candidate genes described above and found
variants in 44 genes that met these criteria. Second, we searched
18,000 rare disease cases from the 100KGP31 and discovered de
novo variants in undiagnosed patients with intellectual disability
in 47 of the 163 genes in our candidate set. Lastly, the CMG, a
collaborative network of centres to discover new genes respon-
sible for Mendelian phenotypes provided a list of phenotypes
studied and potential associated genes39, which included
around 2000 genes. A set of 14 genes overlapping with the 163
DL candidates are classiﬁed as either Tier 1 or Tier 2 genes
(see “Methods”).
We additionally explored denovo-db, a database containing de
novo variants identiﬁed in the literature40, and annotated our set
of 163 prioritised genes with this information. We found at least
one functional de novo variant reported in the database for 108
(66%) genes, of which 83 (51%) contained entries collected from
resources other than DDD2 (Supplementary Data 4).
There was some degree of overlap between the candidates
identiﬁed in the three programmes (Fig. 4a) and for the next stage
we focussed on genes with evidence from both the 100KGP
(where we had detailed patient phenotypes and variant informa-
tion) and either DDD (variants and high-level phenotypes
available) or the CMG (gene and high-level phenotypes available).
We particularly focussed on 9 genes where the associated
variants were not present in any population in gnomAD and
each gene was also not highly tolerant to missense variation
(o/e missense < 0.8; Fig. 4b, Supplementary Data 4). For these
genes, further evidence for candidacy was gathered based on the
number of unrelated families and phenotypic similarities between
them, protein–protein interactions with known developmental
disorder genes, embryonic and adult mouse gene expression in
relevant tissues and embryonic and adult mouse phenotypes that
recapitulate the clinical phenotypes. Here we present two
examples, VPS4A and TMEM63B, where the patient phenotype
and genetic evidence is compelling as well as showing pheno-
copying in the mouse where the IMPC has produced the ﬁrst
knockout lines for these genes. For the other 7 genes (ATP6V0A1,
MAEA, CMIP, PKN2, SPTBN1, RBMS1 and PUM2), there was
functional data supporting the association, but the patient
evidence is currently less strong as we only have single,
intellectual disability cases with detailed clinical phenotypes, or
de novo variants are also observed in cases affected with other
types of rare disease.
VPS4A (HGNC:13488, vacuolar protein sorting 4 homologue
A) had no previously reported pathogenic variants and is highly
intolerant to LoF and missense variants (gnomAD v.2.1., pLI=
0.928, o/e LoF= 0.139, o/e missense= 0.532). De novo variants
in VPS4A were detected in two unsolved, 100KGP intellectual
disability cases but not in any of the other 18,000 cases
representing most types of rare disease. These variants are not
observed in gnomAD and both patients exhibited consistent
intellectual disability, developmental delay, delayed motor devel-
opment, microcephaly and eye abnormalities, including cataracts
(Supplementary Table 7, Supplementary Fig. 6). In addition, a
Tier 2 CMG candidate was described with similar phenotypes of
microcephaly, epilepsy, frontoencephalocele, right spastic hemi-
paresis and psychosocial retardation (Supplementary Table 7,
Supplementary Fig. 6). The IMPC’s data for the ﬁrst mouse
knockout of the orthologous Vps4a gene indicated preweaning
lethality of the homozygotes and, in the case of the heterozygotes,
abnormal skin morphology, enlarged spleen and lens opacity,
potentially modelling the eye phenotypes seen in the patients.
LacZ staining in E12.5 embryos showed widespread expression.
While the LoF mutants are lethal at P14, secondary viability of
Vps4amutants shows that they are viable at E18.5 (6/30, 20%) but
display gross abnormalities at manual observation and by micro-
computed tomography (microCT) imaging. Homozygous Vps4a
E18.5 embryos are smaller than wild types (WTs), with abnormal
body curvature, omphalocele, small and compressed heart,
abnormal spinal cord curvature and abnormal brain develop-
ment. Within the brain, microCT images showed evidence of
abnormalities in the thalamus, thinning of the midbrain and a
smaller cerebellum and pons compared to the WT littermates.
Fig. 2 FUSIL categories and human gene features. a Notched box plots showing the distribution of recombination rates for the different FUSIL bins.
Human recombination rates58 were mapped to the closest gene and average recombination rates per gene were computed. b Distribution of human gene
expression values for different tissues. Median logTPM expression values from the GTEx database for selected non-correlated tissues are shown.
c Protein–protein interaction network parameters. Notched box plots showing the distribution of degree and topological coefﬁcient computed from human
protein–protein interaction data extracted from STRING. Only high-conﬁdence interactions, deﬁned as those with a combined score of >0.7, were kept.
d Protein complexes. Bar plots representing the percentage of genes in each FUSIL bin being part of a protein complex (human protein complexes).
e Paralogues. The bar plot shows the percentage of genes without a protein-coding paralogue gene in each FUSIL bin. Paralogues of human genes were
obtained from Ensembl Genes 95. A cut-off of 30% amino acid similarity was used. f Probability of mutation. Distribution of gene-speciﬁc probabilities of
mutation from Samocha et al.65. g Transcript length. Maximum transcript lengths among all the associated gene transcripts (Ensembl Genes 95, hsapiens
data set). h GIMS Selection Score. Distribution of Gene-level Integrated Metric of negative Selection (GIMS)66 scores across the different FUSIL bins.
i Probability of loss-of-function intolerance (pLI) retrieved from gnomAD2.1. Notched box plots and density plots showing the bimodal distribution of this
score, with higher values indicating more intolerance to variation. j Distribution of gnomAD o/e LoF scores. Upper bound fraction of the conﬁdence interval
around the observed versus expected LoF score ratio (gnomAD 2.1.). A score <0.35 (dashed line) has been suggested to identify intolerant to LoF variation
genes56. For a–c, f, g–j: centre line, median; notch, CI around the median; box edges, interquartile range, 75th and 25th percentile, respectively; whiskers,
1.5 times the interquartile range; outliers not shown. Signiﬁcance for pairwise comparisons for all features is shown in Supplementary Tables 4 and 5. CL
cellular lethal (pink), DL developmental lethal (orange), SV subviable (yellow), VP viable with phenotypic abnormalities (light blue), VN viable with normal
phenotype (dark blue).
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The volume changes of the midbrain/cerebellum/pons might also
be related to the enlargement of the fourth ventricle (Fig. 4c).
Interestingly, VPS4A is known to directly interact in humans with
an intellectual disability gene, CHMP1A, from nuclear magnetic
resonance, afﬁnity chromatography, pull down and two hybrid
assays, and both are part of the necroptosis and endocytosis
pathways41. Variants in CHMP1A cause pontocerebellar hypo-
plasia type 8 (OMIM:614961), with similar phenotypes to patients
with VPS4A variants: severe psychomotor retardation, pontocer-
ebellar hypoplasia, decreased cerebral white matter, thin corpus
callosum, abnormal movements, hypotonia, spasticity, and
variable visual defects. High gene expression levels are present
across all tissues as measured in humans (GTEx data), both
disease and non-disease related. Similarly, high levels of
expression were also seen in WT mouse embryos from 4 to
36 somites according to Deciphering the Mechanism of
Developmental Disorders (DMDD)42. In addition, we found
two de novo variants reported in denovo-db database40: a
nonsense (stop-gained) variant with an associated intellectual
disability phenotype and a missense variant in a patient with
autism. None of these variants are present in gnomAD.
TMEM63B (HGNC:17735, transmembrane protein 63B) is also
extremely intolerant to LoF and missense variants (gnomaD v.
2.1., pLI= 1.00, o/e LoF= 0.07, o/e missense= 0.475) but has no
previously reported pathogenic variants. De novo variants in
unsolved, developmental disorder cases were identiﬁed in 1 DDD
case and 4 unrelated 100KGP participants with intellectual
disability but none of the other 18,000 100KGP cases
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(Supplementary Table 8). These variants are not observed in
gnomAD and the exact same variant (ENST00000259746:
c.130G>A) was detected in three of the families, causing a
p.44Val>Met change in a transmembrane helix that is predicted
to be pathogenic. The clinical data available from the four
100KGP cases showed consistent intellectual disability and
abnormal movement and brain morphology phenotypes, with
seizures also observed in three of the patients (Supplementary
Table 8, Supplementary Fig. 7). For the DDD case, the high-level
phenotypes available were consistent with the 100KGP cases.
IMPC data for the ﬁrst mouse knockout of the orthologous
Tmem63b gene showed preweaning lethality of the homozygotes
and, in the case of the heterozygotes, abnormal behaviour,
hyperactivity and limb-grasping phenotypes that are consistent
with the human patients. Expression analysis placed TMEM63B
in a cluster of genes that are expressed at medium levels from
early to late development. High levels of gene expression in
disease-related tissues, particularly for the brain cerebellum and
muscular–skeletal tissues, were identiﬁed in humans (GTEx data).
High levels of expression were also seen across all mouse
embryonic developmental stages according to DMDD, with GXD
data and the IMPC’s mouse embryo lacZ annotation supporting
neuronal expression during development (Fig. 4d).
Discussion
The diagnostic rate of large-scale, rare disease sequencing pro-
grammes ranges from 20% to 40%31,43, leaving the majority of
patients without a diagnosis and with the associated personal,
psycho-social and healthcare cost this entails. New disease-
associated gene discovery methods are needed to complement
current sequencing approaches44. Here we demonstrate that the
FUSIL categorisation of gene essentiality, combined with intol-
erance to variation scores, patient phenotypes and their overlap
with those observed in mouse lines with null alleles can assist in
the prioritisation of disease–causal variant candidates. We show
an enrichment for disease genes among developmental lethal
genes, which is consistent with the proposed model where
disease-associated genes occupy an intermediate position between
highly essential and non-essential genes28,45. In this model, highly
essential genes will not be associated with human diseases because
any function-altering mutation will likely lead to miscarriage or
early embryonic death. The set of cellular lethal genes is indeed
enriched for pathways associated with developmental disorders,
but the minimal enrichment in developmental disease-associated
genes may be explained by embryonic lethality at a very early
stage of development33. Our results provide further evidence that
highly essential genes needed for cellular processes are less likely
to be associated with disease than developmental essential genes,
suggesting a new complementary approach for ﬁnding such dis-
ease genes and understanding disease mechanisms.
An interesting ﬁnding was the dichotomy of trends observed
for gene-associated features (Fig. 2). We replicated previously
observed trends where genetic features are most differentiated
between the two ends of the FUSIL spectrum, e.g. genes with
paralogues, gene expression, number of protein–protein interac-
tions or the likelihood of being part of a protein complex15,28,35.
The CL bin showed the lowest rates of recombination, and both
the CL and DL fractions exhibited signiﬁcantly lower rates than
the viable categories. This is consistent with previous ﬁndings that
genes with essential cell functions, and showing accumulation of
disease-associated mutations, concentrate in genomic regions
with suppressed recombination34. The strong enrichment of CL
genes for the presence in protein complexes and a lack of para-
logues would suggest that these genes should be particularly
intolerant to damaging mutations with no functional compen-
sation to buffer critical cell processes15,46. For other gene features
associated with mutational rate, the trends peak in the DL and SV
bins, leading to the counter-intuitive observation that CL genes
are less constrained against variation than DL genes; however, the
differences between these two categories are non-signiﬁcant for
the different constraint scores evaluated. The signiﬁcant enrich-
ment for longer transcript lengths and Mendelian disease genes
aligns with previous observations that disease genes tend to be
longer47, and genetic variant intolerance metrics such as shet, pLI
and o/e LoF are highly dependent on gene length7,13.
Recent analysis from the DDD study estimates that de novo
heterozygous variants will be the cause of nearly half of
all undiagnosed, non-consanguineous individuals with develop-
mental disorders37. Since these early-onset disorders are parti-
cularly overrepresented among developmental lethal genes, we
focussed on a set of unsolved developmental disorder cases from
DDD, the 100KGP and CMG. We identiﬁed 82 disease candidates
among the 163 highly LoF intolerant genes from the DL fraction
not previously associated with Mendelian disease. Nine genes in
particular were observed in multiple consortia and are based on
de novo variants in unsolved cases of developmental disorders
that have never been observed in the general population. Further
exploration of overlapping genotypes and phenotypes between
the patients and with embryonic and adult mouse phenotype
evidence from the IMPC, alongside evidence from expression and
Fig. 3 Human disease genes and FUSIL bins. a Enrichment analysis of Mendelian disease genes. Combined OMIM-ORPHANET data was used to compute
the number of disease genes in each FUSIL bin. Odds ratios were calculated by unconditional maximum likelihood estimation (Wald) and conﬁdence
intervals (CIs) using the normal approximation, with the corresponding adjusted P values for Fisher’s exact test. b Distribution of disease-associated genes
according to mode of inheritance. Disease genes with annotations regarding the mode of inheritance according to the Human Phenotype Ontology8.
c Haploinsufﬁcient genes. Known haploinsufﬁcient genes curated by ClinGen (percentage with respect to the total number of disease genes in each bin).
d Age of onset as described in rare diseases epidemiological data from Orphanet (Orphadata). The earliest age of onset associated with each gene was
used. Bar plots representing the percentage of disease genes associated with each age of onset for each FUSIL category. e Distribution of the number of
physiological systems affected. The phenotypes (HPO) associated with each gene were mapped to the top level of the ontology to compute the number of
unique physiological systems affected. f Enrichment analysis of developmental disorder genes. The Developmental Disorders Genotype-Phenotype
Database (DDD-DDG2P) set of genes was used to compute the number of developmental disorder genes in each FUSIL bin. These genes were compared
against non-disease genes (OMIM, ORPHANET and DDD-DD2GP). Odds ratios were calculated by unconditional maximum likelihood estimation (Wald)
and conﬁdence intervals (CIs) using the normal approximation, with the corresponding adjusted P values for Fisher’s exact test. g Distribution of disease
genes. Percentage of distribution of Mendelian and developmental disorder genes among the different FUSIL categories. h Distribution of disease genes by
mode of inheritance. Percentage of distribution of Mendelian and developmental disorder genes among the different FUSIL categories according to the
mode of inheritance reported in the HPO (set of Mendelian disease genes) and DDD (developmental disease-associated genes). CL cellular lethal (pink),
DL developmental lethal (orange), SV subviable (yellow), VP viable with phenotypic abnormalities (light blue), VN viable with normal phenotype (dark
blue), DDD/DDD-DDG2P Deciphering Developmental Disorders database of genes that are likely causative of developmental disorders. For e, centre line,
median; notch, CI around the median; box edges, interquartile range, 75th and 25th percentile, respectively; whiskers, 1.5 times the interquartile range.
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protein–protein interactions with known developmental disorder
genes, further supported these associations. Two genes were
particularly compelling disease candidates from a clinical per-
spective, as gene variants were only observed in patients with
intellectual disability belonging to multiple, unrelated families
with speciﬁc phenotypes in common. One de novo variant in
TMEM63B was observed in three DDD and 100KGP patients
with consistent intellectual disability, movement and brain mor-
phology phenotypes that were recapitulated in the IMPC
Tmem63b mutant mouse. Concordant phenotypes were also
observed between 3 patients with VPS4A variants from the CMG
and 100KGP programs and the E18.5 mutant mouse embryos
from the IMPC. Future identiﬁcation of other families with
similar variants segregating with disease and functional char-
acterisation of the speciﬁc human variants will be required to
establish a deﬁnitive role for these genes in disease. The IMPC
partners are already supporting the CMG, 100KGP, other disease
sequencing projects such as KidsFirst and the wider rare disease
community through CRISPR/Cas9 production and phenotyping
of mouse lines modelling patient-speciﬁc, potentially pathogenic
variants.
Cross-species data integration is not without its limitations.
Not all human genes have a clear one-to-one orthologue in the
mouse genome. In addition, a signiﬁcant proportion of the mouse
protein-coding genome is not yet phenotyped by the IMPC and is
lacking viability data. In this investigation, we chose to focus on
high-quality, IMPC viability calls based on robust statistical
methodologies and not to integrate the numerous, additional data
from literature curation of mice with knockout alleles because
the variation in methods, genetic context and gene targeting
approach are known to affect embryonic lethality. Indeed, we
observed a ~10% disagreement between embryonic lethality
published in the literature on a variety of genetic backgrounds
versus the IMPC observations made exclusively on an inbred
C57BL/6N background (“Methods” and Supplementary Fig. 8).
Human cell line data also has caveats, including the haploid and
1) Small/hunched embryo. 2) Omphalocele. 3) Abnormal heart (small/compressed). 4) Abnormal/curved spine. 
5) Abnormal brain (enlarged 4th ventricle (coronal)), thinning of the mid-hindbrain (saggital).
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PhenoDigm phenotypic similarity
ORPHA:2274 Ichthyosis - hepatosplenomegaly -
cerebellar degeneration syndrome (67.98)
OMIM:261800 Pierre Robin syndrome (67.11)
Parameter: distance travelled - procedure: open field
PhenoDigm phenotypic similarity
OMIM:143465 Attention deficit - hyperactivity 
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DECIHPER:19 Potocki - Lupski syndrome (66.19)
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Fig. 4 Developmental disorders gene candidate prioritisation. a Venn diagram showing the overlap between DL prioritised genes with evidence from 3
large-scale sequencing programmes. Overlap between the set of 163 developmental genes highly intolerant to LoF variation (pLI > 0.90 or o/e LoF upper
bound < 0.35 or HI < 10) and not yet associated with disease and the set of candidate genes from three large rare disease sequencing consortia: 100KGP,
CMG, and DDD. b Set of nine candidate genes. The selected genes met the following criteria: (1) evidence from both the 100KGP (with detailed clinical
phenotypes and variants) and either DDD (variants and high-level phenotypes available) or CMG (gene and high-level phenotypes available), (2) the
associated variants were not present in gnomAD, and (3) intolerance to missense variation; these genes were further prioritised based on the number of
unrelated probands and the phenotypic similarity between them and the existence of a mouse knockout line with embryo and adult phenotypes that mimic
the clinical phenotypes. c Mouse evidence for VPS4A. IMPC embryonic phenotyping of homozygous mutants at E18.5 showed abnormal/curved spine and
abnormal brain among other relevant phenotypes. The phenotypic abnormalities observed in heterozygous knockout mice include lens opacity.
Heterozygous mouse phenotypic similarity to known disorders as computed by the PhenoDigm algorithm. d Mouse evidence for TMEM63B. IMPC
homozygous mouse embryo lacZ imaging at E14.5 supporting neuronal expression during development. Heterozygous IMPC knockout mice associated
phenotypes included abnormal behaviour evaluated through different parameters. The heterozygous mice showed a high phenotypic similarity with several
developmental disorder phenotypes. VUS variant of unknown signiﬁcance.
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immortalised nature of some of the cell lines. The gene constraint
scores based on human sequencing data primarily identify
selection against heterozygous variation and may fail to detect
short genes, recessively acting genes or HI status48, while the
homozygous viability screens in knockout mice typically measure
recessive effects. Hence, a moderate overlap between the set of
essential genes identiﬁed through the different approaches is to be
expected13. Further investigation into haploinsufﬁcient, essential
genes in the mouse is more technically challenging but may reveal
further disease candidates. Combining approaches to compute
intolerance to LoF, e.g. integrating FUSIL bins with other con-
straint scores, improves the ability to identify disease-associated
genes compared to the performance of standalone metrics
(Supplementary Fig. 9). Moreover, although in the present study
we have targeted a particular category of disorders, an additional
feature offered by the FUSIL framework is the ability to utilise all
the bins to focus on other types of disease, including those
associated with late-onset, less severe phenotypes or recessive
mode of inheritance. Alternative approaches integrating different
strategies of gene prioritisation are expected to follow, acting as
an accelerator in Mendelian disease-associated gene discovery.
In summary, this study highlights how the information on gene
essentiality may be used to prioritise potential pathogenic variants
in unknown disease genes from human sequencing studies.
Clinical researchers assessing candidate disease genes should
consider using high-quality model organism data in conjunction
with gene constraint scores from human sequencing projects. We
intend to incorporate such data into our Exomiser variant
prioritisation tool49, which together with patient phenotypes, may
facilitate the genetic diagnosis by prioritising genes in the relevant
FUSIL category. Large-scale projects such as the IMPC, the
gnomAD resource and Project Achilles are continuing to generate
larger data sets, making the resources richer and more robust for
these analyses. Future work will explore the mechanisms behind
how these redeﬁned essential categories correlate to other func-
tional attributes and, ultimately, the evolutionary constraints
imposed upon gene essentiality.
Methods
Main data sets. In this study, we examined genes with viability data for null
homozygote mice produced by the IMPC (https://www.mousephenotype.org). We
obtained high-to-moderate-conﬁdence human orthologues and integrated selected
human genetic data. In particular, we incorporated gene viability data obtained in
human cell screens (initially 11 cell lines corresponding to three studies)18; in this
study, we used the Project Achilles Avana data set comprising 485 cell lines (release
18Q3 of August 2018), which is part of the Cancer Dependency Map (DepMap)
project19. We also incorporated constraint scores (shet, Residual Variation Intol-
erance Score (RVIS), pLI and o/e LoF), disease information (OMIM, ORPHANET,
HPO, DDD) and DMDD annotations (see below for details). We used HGNC and
Mouse Genome Informatics (MGI) as stable identiﬁers in our analysis to avoid
problems associated with gene symbol changes (synonyms and previous symbols,
which may lead to ambiguous identiﬁers) [https://www.genenames.org/download/
statistics-and-ﬁles/; HGNC protein-coding gene ﬁle, downloaded 18.11.14].
IMPC primary and embryo viability assessment. We conducted an analysis on
4934 genes with primary adult viability data currently available in IMPC Data
Release (DR) 9.1. This release included the 1751 genes analysed in Dickinson
et al.21 and the 4237 genes analysed in Munoz-Fuentes et al.18, corresponding to
DR4.0 and DR7.0, respectively, and additional data collected since then.
Viability data generated by the IMPC was analysed as deﬁned in IMPRESS (the
International Mouse Phenotyping Resource of Standardised Screens, https://www.
mousephenotype.org/impress/). A minimum of 28 pups were genotyped before
weaning, and the absence of knockout (null) homozygote pups would classify the
gene as lethal. Thus lethal lines are deﬁned as those with an absence of live null
homozygous pups, while subviable lines are those with <12.5% live homozygous
pups (half of the 25% expected; P < 0.05, binomial distribution). Viable mouse lines
are those for which homozygous (null and WT) and heterozygous pups are
observed in normal Mendelian ratios. A viable call was also made when there were
<28 total pups and homozygous null pups ≥ 4 (as this would result in ≥14%
homozygous pups when 28 pups were genotyped). We ﬁltered out genes for which
sample size was insufﬁcient (total pups < 28, n= 1 gene) and hemizygous genes
(n= 13 genes), as well as those with conﬂicting calls (genes that appear in more
than one viability category, n= 34 genes). The resulting set comprises 4886 genes,
of which 1171 had a lethal phenotype, 449 a subviable phenotype, and 3266 a viable
phenotype (24%, 9% and 67%, respectively).
The IMPC also implements a dedicated embryonic pipeline for lethal lines, in
which null homozygous embryo viability is assessed at selected stages during
embryonic development, including E9.5, E12.5, E14.5–E15.5 and E18.5. Viability at
a given stage is assessed by scoring homozygous embryos for the presence of a
heartbeat at dissection, as described in Dickinson et al.21. To establish windows of
lethality, we considered a gene lethal at a given stage if no live homozygous
embryos were identiﬁed after scoring at least 28 live embryos and viable if any live
homozygous embryos were identiﬁed, irrespective of additional phenotype features.
Following Dickinson et al.21, we deﬁned windows of lethality as “prior to E9.5”,
“E9.5–E12.5”, “E12.5–E14.5/E15.5”, “E15.5–E18.5”, “after E14.5/E15.5”, and “after
E18.5”. Lines with incomplete data to deﬁne these windows were excluded. For this
study, windows were combined to yield three functional groups: early (gestation)
lethal (prior to E9.5), intermediate (mid-gestation) lethal (E9.5–E12.5,
E12.5–E14.5/E15.5), and late (gestation) lethal (E14.5/E15.5–E18.5, after E14.5/
E15.5 and after E18.5). Out of 523 for which secondary screen data are available,
400 could be assigned to one of the described windows. Additional time points are
required to complete the window assignment for the remaining 123 genes
(Supplementary Table 3).
Orthologue mapping. Orthologues were obtained using the HCOP tool developed
by HGNC, based on 12 established inference methods (https://www.genenames.
org/tools/hcop/; HCOP ﬁle with human and mouse orthologue inferences down-
loaded 18.10.31). We determined the conﬁdence on the orthologue prediction
based on the number of methods that supported each inference (12–9 methods,
100–75%, good-conﬁdence orthologue; 8–5, 67–42%, moderate-conﬁdence ortho-
logue; 4–1, 33–8%, low-conﬁdence orthologue; 0 no orthologue). We kept ortho-
logues for which at least one gene, the human or the mouse gene, was protein
coding and the orthologue inference score was ≥5. Of those, we kept genes for
which the score was maximum in both directions, mouse to human and human to
mouse (and also ﬁltered out genes with duplicated maximum scores). This resulted
in 4664 genes. Of these, 33 genes with IMPC conﬂicting viability phenotypes and
17 genes with no adult viability data and insufﬁcient embryo data to call a viability
phenotype were not considered further. Among the remaining 4614 genes, 1185
(26%) genes had a lethal phenotype, 443 (9%) a subviable phenotype, and 2986
(65%) a viable phenotype. Of these, 4446 genes had human cell viability data
(Avana data set; see next section).
Essentiality in human cells. In our previous study18, we used viability data as
reported for 11 cell lines from 3 studies15–17. Here we used the Project Achilles
Avana data set and CRISPR-Cas9 proliferation (essentiality) scores, which is part of
the Cancer Dependency Map (DepMap) project21. This data set comprises viability
data on 17,634 genes in 485 cell lines (https://depmap.org/portal/achilles/; release
18Q3 in August 2018), with lower values indicating more intolerance (i.e. more
essential). The Avana data set presents several advantages as compared to the
previous studies. It is a larger data set, viability is measured using the same units for
all cell lines (allowing us to obtain a mean per gene) and the data are corrected for
copy number variation20. Gene identiﬁers were provided as Entrez identiﬁers
(NCBI) and converted to HGNC identiﬁers.
Determining functional bins. For each gene, we obtained a mean of the Avana
proliferation scores and integrated with our data set of mouse genes with viability
data based on the mouse-to-human orthologues (obtained as described above).
We observed that, for genes with an Avana mean score < −0.45, the mouse null
homozygotes were lethal in almost all cases, while genes with an Avana mean score
>−0.45 presented lethal, subviable or viable phenotypes (Supplementary Fig. 1a,
Supplementary Fig. 1b). A similar pattern was observed when a different resource
for cell essentiality—based on 11 cell lines from 3 different studies—was used
(methods and threshold criteria explained in Munoz-Fuentes et al.18 (Supple-
mentary Fig. 1c).
F1 scores were derived from confusion matrices generated when considering
different Avana mean scores and the classiﬁcation from the previous studies, and a
mean score cut-off of −0.45 was found to maximise the F1 scores across the
different data sets (Supplementary Fig. 1d, Table 1, Supplementary Table 1). We
therefore set a threshold where genes with a mean Avana ≤ −0.45 were considered
essential in cell lines, while the set >−0.45 corresponded to cellular non-essential
genes. Based on all this evidence, we categorised two sets of genes, Cellular Lethal
(CL) and Developmental Lethal (DL) genes, comprising 413 and 764 genes,
respectively (Table 1).
Genes with a subviable or viable phenotype were classiﬁed for their human
orthologue almost in all cases as non-essential (Avana mean score for each gene
>−0.45), except for 16 and 22 genes for the subviable and viable categories,
respectively, which had a mean Avana scores below but very close to the
−0.45 threshold). These genes were non-essential based on data from the three
human cell studies. Thus we distinguish a Subviable group (SV) with Avana mean
score >−0.45, as well as two outlier groups, SV.outlier and V.outlier, with Avana
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mean score ≤ −0.45. We classiﬁed viable genes further, into those with at least one
IMPC signiﬁcant phenotype (VP) or no IMPC signiﬁcant phenotypes (VN). A
number of viable genes (n= 627) had <50% phenotype procedures obtained so far
(the IMPC releases are snapshots of ongoing characterisation for many lines), and
thus we termed them V.insuffProcedures (Supplementary Table 1).
These categories, established using the Avana cell scores, were almost identical
(96% concordance) to those established using a gene essentiality classiﬁcation
(essential/non-essential) based on the 11 cell lines from 3 studies18.
All the subsequent analysis focussed on the main ﬁve FUSIL bins: CL, DL, SV, VP,
and VN. Sankey diagrams representing the mappings between mouse and human cell
essentiality categories were plotted with the R package alluvial50. GO BP enrichment
was conducted with the R package category51, with the entire set of IMPC genes as the
reference set. The Benjamin and Hochberg (BH) method was applied for multiple
testing correction52 and an adjusted P value < 0.05 was considered signiﬁcant. The
results were plotted using the REVIGO algorithm for semantic similarity and
redundancy reduction53. The algorithm selects representative GO terms out of the
signiﬁcant results, maximising semantic representation and enriched/statistical
signiﬁcance (settings: SimRel semantic similarity measure, medium similarity, Homo
sapiens database). Signiﬁcant results were only found for the CL and DL gene
categories. In Fig. 1b, the bubble size is proportional to the frequency of the term in
the database and the colour indicates the signiﬁcance level as obtained in the
enrichment analysis, after correcting for multiple testing.
Reactome pathway enrichment analysis was performed by means of the R/
Bioconductor package ReactomePA54. The same approach for multiple testing
correction followed in the GO analysis was applied.
Previous knowledge on mouse viability. The IMPC is an ongoing project. Given
that about ¼ of the mouse genome has been screened for viability to date, we
decided to compare our results with previous annotations from MGI55. We found a
total of 4599 mouse genes with embryo lethality annotations (50 Mammalian
Phenotype Ontology terms as described in Dickinson et al.21) once conditional
mutations were excluded from a total of 13,086 genes with any phenotypic
annotation (including normal phenotype). That would mean that approximately
35% of the genes for which a knockout mouse has been reported in the literature
and curated by the MGI showed some type of embryo/perinatal lethality. As the
MGI resource also includes IMPC data, we subsequently excluded those
gene–phenotype associations corresponding to IMPC alleles. This results in 9254
mouse genes with phenotypic annotations other than IMPC with a PubMed ID
(old papers with no abstract available, conference abstracts and direct data sub-
missions were therefore excluded for this analysis). For 3362 (36%) of these genes,
we found annotations related to embryonic lethality.
Even though the procedures for determining viability may differ from the
standardised viability protocol followed by the IMPC, this percentage is very close
to that found using IMPC data, with 26% of the screened genes lethal and 10% of
the screened genes subviable. For 2115 mouse genes with both IMPC and non-
IMPC phenotypic annotations available to infer viability, we found discrepancies
for a set of 63 genes that were scored as lethal by the IMPC and with no previous
records of lethality in MGI, as well as 154 genes scored as viable by the IMPC and
with some type of lethality annotation reported in MGI (Supplementary Fig. 8,
Supplementary Table 9; Mouse Genome Database at the Mouse Genome
Informatics website [http://www.informatics.jax.org; MGI_GenePheno.rpt; data
accessed 19.02.06]).
Constraint scores based on human population data. The RVIS5 was downloaded
from http://genic-intolerance.org/; version CCDSr20, with lower values indicating
more intolerance to variation. Estimates of selection against heterozygous protein-
truncating variants (shet) were obtained from the supplementary material of Cassa
et al.11 with higher values indicating more intolerant to variation. The probability
of a gene being intolerant to LoF (pLI)6, with higher values indicating more
intolerance, the o/e ratio of LoF with the corresponding upper bounds (LOEUF)
the (o/e) ratio of missense and the (o/e) ratio of synonymous alleles, with lower
values indicating more intolerance to variation, were retrieved from gnomAD2.1
(https://gnomad.broadinstitute.org/)7,56. The HI was obtained from the DDD
consortium (https://decipher.sanger.ac.uk/about#downloads/data; downloaded
BED ﬁle, 18.11.27, Haploinsufﬁciency Predictions Version 3)57. High ranks (e.g.
0–10%) indicate a gene is more likely to exhibit HI while low ranks (e.g. 90–100%)
indicate a gene is more likely to not exhibit HI. In all cases, gene identiﬁers were
obtained as symbols and converted to HGNC IDs using the multi-symbol checker
provided by HGNC (https://www.genenames.org/tools/multi-symbol-checker/).
A comparative analysis of FUSIL categories with gnomAD pLI scores was
conducted considering a threshold of pLI > 0.90 to deﬁne highly constrained genes,
i.e. LoF intolerant genes (Supplementary Fig. 9).
Recombination rates. We used the average genetic map computed from the
paternal and maternal human genetic maps from Halldorsson et al.58 (Data S3).
The recombination rate (cMperMb) was provided for genomic intervals, and we
mapped each interval to the closest protein coding gene—Ensembl 96 GRCh 38—
(upstream or downstream) by means of R_bedtools_closest function in HelloR-
anges library59. Gene positions were obtained through biomaRt60. Once we
assigned the recombination rates for the intervals provided to a certain gene,
average recombination rates per gene were computed.
Gene expression. Human gene median transcripts per kilobase million (TPM)
values by tissue were downloaded from the GTEx portal [https://gtexportal.org/
home/datasets; accessed 18.12.02, ﬁle “GTEx_Analysis_2016-01-15_v7_RNA-
SeQCv1.1.8_gene_median_tpm.gct.gz”]61. Gene symbols were mapped to HGNC
ID identiﬁers. Spearman correlation coefﬁcients between gene expression values
across tissues were estimated, only TPM values for relevant (non-correlated) tissues
were considered for further analysis.
Protein–protein interaction data. Human protein–protein interaction data were
downloaded from STRING website [accessed 18.11.18]. Only high-conﬁdence
interactions, deﬁned as those with a combined score >0.7 were used for further
analysis62. Ensembl protein IDs were mapped to HGNC IDs using Ensembl bio-
maRt (Ensembl Genes 94)60. Several network parameters for every node in the
network were computed with Cytoscape (v3.5.1) plug-in Network Analyzer63.
Spearman correlation coefﬁcients between different network parameters were
estimated; only non-correlated parameters were considered for further analysis.
Protein complexes. A core set of human protein complexes was downloaded from
Corum 3.064 (http://mips.helmholtz-muenchen.de/corum/#download; accessed
18.12.03). Gene symbols were mapped to unambiguous HGNC ID identiﬁers
corresponding to protein-coding genes.
Paralogues. Paralogues were retrieved with biomaRt (https://www.ensembl.org/
index.html;Ensembl; Genes 95 version [data accessed 19.02.18])60. Only genes with
HGNC IDs were considered, and only those protein-coding paralogues with an
HGNC ID were kept for downstream analysis. A cut-off of 30 for the percentage of
identical amino acids in the paralogue compared with the gene of interest was used
for the computation.
Probability of mutation. Per-gene probabilities of mutations (all types of muta-
tions) were obtained from Samocha et al.65. Gene symbols were mapped to HGNC
IDs (Probabilities are shown as 10^all).
Transcript length. Transcript lengths were retrieved with biomaRt R package
(Ensembl Genes 96, hsapiens_gene_ensembl data set)60. For each HGNC ID, the
maximum transcript lengths was computed from all the gene transcripts.
Selection scores. GIMS scores, which combine multiple comparative genomics
and population genetics to measure the strength of negative selection, were
obtained from Sampson et al.66. (Table_S1). Gene symbols were mapped to
unambiguous HGNC ID identiﬁers.
Gene–disease associations. Disease-associated genes curated by OMIM (https://
omim.org/) and Orphanet (https://www.orpha.net) were analysed through our
PhenoDigm pipeline67 [Data accessed 19.01.16]. DECIPHER developmental dis-
orders genes are deﬁned as those reported to be associated with developmental
disorders, compiled by clinicians as part of the DDD study to facilitate clinical
feedback of likely causal variants. The DDG2P3 is categorised into the level of
certainty that the gene causes developmental disease (conﬁrmed or probable), the
consequence of a mutation (LoF, activating, etc.) and the allelic status associated
with disease (monoallelic, biallelic, etc.) [DDG2P version: DDG2P_19_2_2019.csv;
https://decipher.sanger.ac.uk/ddd#ddgenes].
Given that OMIM contains a certain number of genes involved in susceptibility to
multifactorial disorders and other non-Mendelian gene–disease associations and that
DDD-DDG2P also includes probable and possible gene–disease associations, we
decided to investigate additional sets of curated gene–disease associations. In
particular, we explored the gene panels curated by Genomics England and
incorporated in its PanelAPP. Only those genes categorised as “green”, i.e. there is a
high level of evidence for the gene–disease association, and therefore are considered as
diagnostic grade, were explored. Five different sets of genes were analysed: one
corresponding to the total set of “green” genes included in any Genomics England
gene panel (PanelAPP, 285 panels with at least one gene classiﬁed as green) and those
genes belonging to the following panels: DDG2P (Developmental disorders, set of
“green” genes from DDG2P panel, which contains a subset of DDG2P genes with one
of the following levels of evidence: Conﬁrmed or both DD and IF), PD (set of “green”
genes from the Paediatric disorders gene panel), ID (set of “green” genes from the
Intellectual disability gene panel) and FA (set of “green” genes from the foetal
anomalies panel, which contains a subset of genes associated with developmental
disorders developed by the PAGE study (Prenatal Assessment of Genomes and
Exomes) with a conﬁrmed disease conﬁdence rating that underwent additional review
and curation) [https://panelapp.genomicsengland.co.uk; data accessed 19.06.02].
Mode of inheritance and physiological systems affected. Mode of inheritance
and number of physiological systems affected were annotated for each gene
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14284-2 ARTICLE
NATURE COMMUNICATIONS |          (2020) 11:655 | https://doi.org/10.1038/s41467-020-14284-2 | www.nature.com/naturecommunications 11
according to Human Phenotype Ontology annotations [https://hpo.jax.org/app/
download/annotation; downloaded 19.02.19]. The ﬁle ALL_SOURCES_ALL_-
FREQUENCIES_genes_to_phenotype.txt provides a link between genes and
HPO terms8. AR inheritance (HP:0000007) and AD inheritance (HP:0000006)
annotations were selected for downstream analysis. Phenotype ontology terms
associated with each gene were mapped to the top level of the HPO to compute
the number of unique physiological systems affected.
An additional set of haploinsufﬁcient genes from ClinGen68 (https://www.
clinicalgenome.org/) (n= 295) was used for the analysis [https://github.com/
macarthur-lab/gene_lists; data accessed 19.02.19].
Genomics England PanelAPP also contain information about the mode of
inheritance. We restricted the analysis to those genes associated with one of the
following modes of inheritance: monoallelic, biallelic, or both with consistent
annotation across different panels [https://panelapp.genomicsengland.co.uk; data
accessed 19.06.02].
Age of onset. The age of onset was obtained from rare diseases epidemiological
data (Orphadata) [http://www.orphadata.org/cgi-bin/epidemio.html; data accessed
19.02.13]. The earliest age of onset associated with each gene was selected for
downstream analysis.
Disease gene enrichment. For each FUSIL bin, ORs were computed from a
contingency table with the number of disease and non-disease genes for each one of
the categories versus the remaining set of IMPC genes with FUSIL information. For
each one of the disease categories that were analysed, the corresponding subset of
disease-associated genes was compared to the overall set of non-disease genes. ORs
were calculated by unconditional maximum likelihood estimation (Wald) and
conﬁdence intervals using the normal approximation, with the corresponding two-
sided P values for the test of independence calculated using Fisher’s exact test
(adjusted P values, BH adjustment52).
Candidate genes annotation and prioritisation strategy. A gene set consisting of
those developmental lethal genes (n= 764) that were not associated with a Men-
delian disorder according to OMIM, ORPHANET or DECIPHER (n= 387) and
highly likely to be haploinsufﬁcient (HI % < 10 | o/e lof upper bound < 0.35 | pLI >
0.90) (n= 163) was used to identify candidate genes for undiagnosed cases of
developmental disorders with heterozygous mutations.
Further analysis was conducted to compare our set of 163 prioritised DL genes
with those genes non-associated with disease from the remaining FUSIL bins as
well as with the entire set of genes in each FUSIL bin. We focussed on evaluating
our disease candidate genes against a set of genes associated with developmental
disorders with a monoallelic mode of inheritance reported: the set of DDD
monoallelic “green” genes as curated in Genomics England PanelAPP (n= 291).
We used PFAM protein family annotations (biomaRt, Ensembl Genes 97 version,
hsapiens_gene_ensembl data set [data accessed 19.07.31])60, pathways from
Reactome69 (lowest-level pathways, Homo sapiens) [https://reactome.org/
download/current/Ensembl2Reactome.txt; data accessed 19.07.31] and protein
interactors from STRING62 as explained above (STRING ppI annotations with a
combined score >0.7). We compared our selected set of DL genes with those in the
different FUSIL bins that are not associated with disease and with the entire set of
genes in each FUSIL bin. For each one of the three features (protein families,
pathways and interactors), we computed the percentage of genes in each category
sharing a PFAM protein family, a Reactome pathway (lowest level) or directly
interacting with any monoallelic developmental disease gene.
Deciphering developmental disorders (DDD) research variants (found in
~2000 genes) were downloaded from https://decipher.sanger.ac.uk/ddd#research-
variants [accessed 18.11.05]. This is a set of variants of unknown signiﬁcance found in
4293 children with developmental disorders who participated in the UK DDD study.
It includes functional de novo and rare LoF homozygous, compound heterozygous
and hemizygous variants in genes that are not associated with developmental
disorders and are not reported in OMIM in children who remain undiagnosed in the
DDD study.
CMG1 Tier 1 and Tier 2 level genes (~2000 genes) were obtained from
http://mendelian.org/phenotypes-genes [accessed 19.28.02]. No information about
individual variants is provided.
De novo variants (<0.1% in the 100KGP and public resources such as gnomAD
and predicted to have effect on the coding region of genes) in undiagnosed patients
with intellectual disability from the 100KGP and associated clinical phenotypes
(HPO terms) were extracted by querying the data available in the GeCIP research
environment [accessed 18.10.20] and intersecting with our set of 163
prioritised genes.
Denovo-db database, a resource containing human de novo variants identiﬁed
in the literature40 was also explored. Mainly focussed but not limited to
neurodevelopmental phenotypes and congenital heart disease, it also includes
published de novo variants associated with other phenotypes, e.g. autism, Tourette
syndrome or schizophrenia or controls) [denovo-db, Seattle, WA URL: denovo-db.
gs.washington.edu; data accessed 19.07.24]. Only those variants with a predicted
effect on the coding region were considered for the purpose of this study
(synonymous variants were excluded).
Research candidates were identiﬁed in 82 of the 163 prioritised genes (highly
LoF intolerant not previously been associated with Mendelian disease). Out of the
total number of 47 genes with heterozygous de novo variants from undiagnosed
cases in the 100KGP project and with extensive clinical phenotype available,
19 overlap with genes with heterozygous de novo variants from the DDD set of
research candidates and 4 of them with Tier 1 or Tier 2 genes from CMG (of which
2 were shared between the 3 data sets). We next focussed on this set of overlapping
genes to narrow down the search for strong candidates, and we discarded those
genes where the variants were present at any frequency in gnomAD along with
those intolerant to missense variation (gnomAD o/e missense score < 0.8). This
resulted in 9 genes that were then prioritised based on the presence of unrelated
probands with phenotypic similarities and the existence of knockout mice—with
embryonic and/or adult phenotypes—mimicking the clinical phenotypes.
For the set of candidate genes, expression analysis was conducted using
BrainSpan70 and FUMA Gene2Func71 with all protein-coding genes as a background.
Other mouse annotation resources include: DMDD (https://dmdd.org.uk/),
GXD resource (www.informatics.jax.org/expression.shtml), and IMPC mouse
embryo lacZ imaging (http://www.mousephenotype.org/data/imageComparator?
&parameter_stable_id=IMPC_ELZ_063_001&acc=MGI:2387609).
The phenotypic similarity between the IMPC mouse models and known
disorders was computed by the PhenoDigm algorithm67.
Software. Data analysis and visualisation was performed in R72.
Ethics statement. Mouse production, breeding and phenotyping at each centre was
done in compliance with each centre’s ethical animal care and use guidelines in
addition to the applicable licensing and accrediting bodies, in accordance with the
national legislation under which each centre operates (Animal Welfare and Ethical
Review Body (AWERB), UC Davis Institutional Animal Care and Use Committee
(IACUC), Animal Care Committee (ACC) of the Toronto Centre for Phenogenomics,
IACUC of MARC, The RIKEN Tsukuba Animal Experiments Committee, Com’Eth.
agreement nb: 17, Regierung von Oberbayern, The Jackson Laboratory Institutional
Animal Care and Use Committee (IACUC), Institutional Animal Care and Usage
Committee). All efforts were made to minimise suffering by considerate housing and
husbandry. All phenotyping procedures were examined for potential reﬁnements
disseminated throughout the IMPC. Animal welfare was assessed routinely for
all mice.
All patient data used in this study was either accessed through the public
websites provided by DDD and the CMG or, in the case of the 100KGP, through
the research environment provided by Genomics England and conforming to their
procedures. All participants in the 100KGP have provided written consent to
provide access to their anonymised clinical and genomic data for research
purposes. The 100KGP research and clinical project model and its informed
consent process has been approved by the National Research Ethics Service
Research Ethics Committee for East of England – Cambridge South Research
Ethics Committee.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data that support the ﬁndings of this study are available in the BioStudies database
under accession number S-BSST293. All other data supporting the ﬁndings of the study
are included in the paper or its supplementary information tables. Additional
information on mouse phenotypes is available through the IMPC web portal (https://
www.mousephenotype.org/) and the IMPC FTP repository (ftp://ftp.ebi.ac.uk/pub/
databases/impc/).
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